Results for tag: "Gastric Cancer Diagnostic Procedure"

The Gastric Cancer Diagnostic Procedure market encompasses a range of medical procedures aimed at detecting the presence of cancerous cells or tumors in the stomach. This segment of diagnostics is an important part of the healthcare industry because early detection of stomach cancer can greatly improve patient outcomes. Diagnostic methods for gastric cancer include endoscopic procedures such as esophagogastroduodenoscopy (EGD), during which tissue samples may be collected for biopsy. Imaging tests like computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans are also used to visualize the stomach and assess the extent of the cancer. In addition, laboratory tests that analyze blood, stomach contents, and stool can help in diagnosing gastric cancer. Advances in molecular diagnostics have introduced techniques such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) for the identification of genetic mutations associated with the disease. The market also includes the development of biomarkers that can aid in the early detection and management of gastric cancer. Companies in the gastric cancer diagnostic procedure market include industry leaders and specialized medical technology firms such as Roche Diagnostics, Siemens Healthineers, GE Healthcare, Philips Healthcare, and Olympus Medical Systems. Other players include bioMérieux, Agilent Technologies, Thermo Fisher Scientific, and Abbott Laboratories, each contributing to the development and provision of diagnostic tools and technologies utilized in the detection and evaluation of gastric cancer. Show Less Read more